Skip to main content
Home

Leading research for life changing results

  • Our Role & Impact
    • About HMRI
    • Our People
    • Research Funded through HMRI
    • Foundations
      • HMRI Foundation
      • HMRI Sydney Foundation
      • HCRF
      • HTRF
      • Mark Hughes Foundation
      • Borne HMRI
    • Awards and Recognition
      • Researcher Awards
      • HMRI Exceptional Service
    • Our Partnerships
    • Governance
    • Careers
  • Medical Research
    • Research
    • Researchers
    • News & Articles
    • Participate In Research
    • Coronavirus (COVID-19)
  • Support HMRI
    • Donate Now
    • Your Impact
    • Ways to Donate
    • Fundraise
    • Bequests
    • Volunteer
    • Company Donors
    • Events
      • Upcoming Events
      • Past Events
    • Read the latest Searcher Magazine
  • For Researchers
    • HMRI Connect
    • Clinical Trials Unit
    • Promote Your Work
    • Research Project Support
    • Facilities & Equipment
    • Funding Support
    • Register to be a HMRI Researcher
  • Connect
    • Contact Us
    • Sign up for updates
    • Connect Intranet
  1. Home
  2. Search Results

Search Results

  • All (31)
  • Researcher Profiles (13)
  • News & Articles (11)
  • Research (4) Remove Research (4) filter
  • General (2)
  • For Researchers (1)

Search found 4 items

All
An Investigation on the Consensus Between Different Genomic and Transcriptomic Results in Breast Cancer
Category: Research

The Breast Cancer Translational Research Laboratory J.C. Heuson based at Institut Bordet, in Brussels, uses several molecular approaches to gain a better understanding of breast tumorigenesis, metastasis, and drug resistance.

FU-SAFE: Individual Patient Data Meta-Analysis Evaluating the Link Between Dihydropyrimidine Dehydrogenase (DPD) Genotype and/or Phenotype, and Severe Fluoropyrimidine-Related Toxicity
Category: Research

Fluoropyrimidines (5-FU and capecitabine) are anticancer drugs commonly used in a range of cancers including oesophageal, gastric and colorectal cancers.  Their toxicity is unpredictable, leading to significant and sometimes life-threatening side effects.  Pharmacokinetics (steady state plasma level, area under the curve, etc.) varies between patients by a factor of 5-10, and this is also unpredictable.  Although therapeutic drug monitoring might allow better management of pharmacokinetic variability by rapid dose adjustment, it is labour-intensive and time-consuming.

The genetic determinants of brain haemorrhage associated with stroke thrombolysis
Category: Research

Stroke is the leading cause of long-term disability in Australia and the second leading cause of death.

Joshua - Atkins Emlyn and Jennie Thomas Medical Research Postgraduate Scholarship
Category: Research
... and Consortiums. CNV data I generated was given to the Psychiatric Genomics Consortium for the largest CNV study in history in SZ, which ...
  • View Research & Diseases
  • News & Articles
  • Site Map
  • Privacy Policy
  • Stay Connected
  • HUNTER MEDICAL RESEARCH INSTITUTE ABN 27 081 436 919 Phone (02) 4042 0000 Donation Hotline 1300 993 822
  •  
  • Copyright ©

    All rights reserved

  • Tata Consultancy Services